Blake Wise

Mr. Wise is Chief Executive Officer at Novome Biotechnologies. Previously, Mr. Wise served as Chief Executive Officer and a member of the board of directors of Achaogen, and previously as President and Chief Operating Officer, where he oversaw the development and FDA approval of ZEMDRI (plazomicin) for adults with complicated urinary tract infections. Prior to joining Achaogen, Mr. Wise spent 13 years at Genentech, in multiple leadership positions of increasing responsibility, including Vice President in Genentech’s BioOncology business unit. Prior to joining Genentech, Mr. Wise worked in consumer marketing, e-commerce, and online marketing in leadership positions at Gap, Inc., and Webvan. He received a Bachelor of Arts degree in Business Economics from the University of California, Santa Barbara, and a Masters of Business Administration degree from the University of California, Berkeley, Haas School of Business.